Fatty liver associated with metabolic derangement in patients with chronic kidney disease: A controlled attenuation parameter study

Chang Yun Yoon, Misol Lee, Seung Up Kim, Hyunsun Lim, Tae Ik Chang, Youn Kyung Kee, Seung Gyu Han, In Mee Han, Young Eun Kwon, Kyoung Sook Park, Mi Jung Lee, Jung Tak Park, Seung Hyeok Han, Sang Hoon Ahn, Shin Wook Kang, Tae Hyun Yoo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Hepatic steatosis measured with controlled attenuation parameter (CAP) using transient elastography predicts metabolic syndrome in the general population. We investigated whether CAP predicted metabolic syndrome in chronic kidney disease patients. Methods: CAP was measured with transient elastography in 465 predialysis chronic kidney disease patients (mean age, 57.5 years). Results: The median CAP value was 239 (202-274) dB/m. In 195 (41.9%) patients with metabolic syndrome, diabetes mellitus was more prevalent (105 [53.8%] vs. 71 [26.3%], P < 0.001), with significantly increased urine albumin-to-creatinine ratio (184 [38-706] vs. 56 [16-408] mg/g Cr, P = 0.003), high sensitivity C-reactive protein levels (5.4 [1.4-28.2] vs. 1.7 [0.6-9.9] mg/L, P < 0.001), and CAP (248 [210-302] vs. 226 [196-259] dB/m, P < 0.001). In multiple linear regression analysis, CAP was independently related to body mass index (β = 0.742, P < 0.001), triglyceride levels (β = 2.034, P < 0.001), estimated glomerular filtration rate (β = 0.316, P = 0.001), serum albumin (β = 1.386, P < 0.001), alanine aminotransferase (β = 0.064, P = 0.029), and total bilirubin (β = -0.881, P = 0.009). In multiple logistic regression analysis, increased CAP was independently associated with increased metabolic syndrome risk (per 10 dB/m increase; odds ratio, 1.093; 95% confidence interval, 1.009-1.183; P = 0.029) even after adjusting for multiple confounding factors. Conclusion: Increased CAP measured with transient elastography significantly correlated with and could predict increased metabolic syndrome risk in chronic kidney disease patients.

Original languageEnglish
Pages (from-to)48-57
Number of pages10
JournalKidney Research and Clinical Practice
Volume36
Issue number1
DOIs
Publication statusPublished - 2017 Mar

Fingerprint

Fatty Liver
Chronic Renal Insufficiency
Elasticity Imaging Techniques
Regression Analysis
Alanine Transaminase
Glomerular Filtration Rate
Bilirubin
Serum Albumin
C-Reactive Protein
Albumins
Linear Models
Creatinine
Diabetes Mellitus
Triglycerides
Body Mass Index
Logistic Models
Odds Ratio
Urine
Confidence Intervals
Liver

All Science Journal Classification (ASJC) codes

  • Nephrology
  • Urology

Cite this

Yoon, Chang Yun ; Lee, Misol ; Kim, Seung Up ; Lim, Hyunsun ; Chang, Tae Ik ; Kee, Youn Kyung ; Han, Seung Gyu ; Han, In Mee ; Kwon, Young Eun ; Park, Kyoung Sook ; Lee, Mi Jung ; Park, Jung Tak ; Han, Seung Hyeok ; Ahn, Sang Hoon ; Kang, Shin Wook ; Yoo, Tae Hyun. / Fatty liver associated with metabolic derangement in patients with chronic kidney disease : A controlled attenuation parameter study. In: Kidney Research and Clinical Practice. 2017 ; Vol. 36, No. 1. pp. 48-57.
@article{fb2cf5a729ec45a990e7e56a1b883c10,
title = "Fatty liver associated with metabolic derangement in patients with chronic kidney disease: A controlled attenuation parameter study",
abstract = "Background: Hepatic steatosis measured with controlled attenuation parameter (CAP) using transient elastography predicts metabolic syndrome in the general population. We investigated whether CAP predicted metabolic syndrome in chronic kidney disease patients. Methods: CAP was measured with transient elastography in 465 predialysis chronic kidney disease patients (mean age, 57.5 years). Results: The median CAP value was 239 (202-274) dB/m. In 195 (41.9{\%}) patients with metabolic syndrome, diabetes mellitus was more prevalent (105 [53.8{\%}] vs. 71 [26.3{\%}], P < 0.001), with significantly increased urine albumin-to-creatinine ratio (184 [38-706] vs. 56 [16-408] mg/g Cr, P = 0.003), high sensitivity C-reactive protein levels (5.4 [1.4-28.2] vs. 1.7 [0.6-9.9] mg/L, P < 0.001), and CAP (248 [210-302] vs. 226 [196-259] dB/m, P < 0.001). In multiple linear regression analysis, CAP was independently related to body mass index (β = 0.742, P < 0.001), triglyceride levels (β = 2.034, P < 0.001), estimated glomerular filtration rate (β = 0.316, P = 0.001), serum albumin (β = 1.386, P < 0.001), alanine aminotransferase (β = 0.064, P = 0.029), and total bilirubin (β = -0.881, P = 0.009). In multiple logistic regression analysis, increased CAP was independently associated with increased metabolic syndrome risk (per 10 dB/m increase; odds ratio, 1.093; 95{\%} confidence interval, 1.009-1.183; P = 0.029) even after adjusting for multiple confounding factors. Conclusion: Increased CAP measured with transient elastography significantly correlated with and could predict increased metabolic syndrome risk in chronic kidney disease patients.",
author = "Yoon, {Chang Yun} and Misol Lee and Kim, {Seung Up} and Hyunsun Lim and Chang, {Tae Ik} and Kee, {Youn Kyung} and Han, {Seung Gyu} and Han, {In Mee} and Kwon, {Young Eun} and Park, {Kyoung Sook} and Lee, {Mi Jung} and Park, {Jung Tak} and Han, {Seung Hyeok} and Ahn, {Sang Hoon} and Kang, {Shin Wook} and Yoo, {Tae Hyun}",
year = "2017",
month = "3",
doi = "10.23876/j.krcp.2017.36.1.48",
language = "English",
volume = "36",
pages = "48--57",
journal = "Kidney Research and Clinical Practice",
issn = "2211-9132",
publisher = "Elsevier Korea",
number = "1",

}

Fatty liver associated with metabolic derangement in patients with chronic kidney disease : A controlled attenuation parameter study. / Yoon, Chang Yun; Lee, Misol; Kim, Seung Up; Lim, Hyunsun; Chang, Tae Ik; Kee, Youn Kyung; Han, Seung Gyu; Han, In Mee; Kwon, Young Eun; Park, Kyoung Sook; Lee, Mi Jung; Park, Jung Tak; Han, Seung Hyeok; Ahn, Sang Hoon; Kang, Shin Wook; Yoo, Tae Hyun.

In: Kidney Research and Clinical Practice, Vol. 36, No. 1, 03.2017, p. 48-57.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fatty liver associated with metabolic derangement in patients with chronic kidney disease

T2 - A controlled attenuation parameter study

AU - Yoon, Chang Yun

AU - Lee, Misol

AU - Kim, Seung Up

AU - Lim, Hyunsun

AU - Chang, Tae Ik

AU - Kee, Youn Kyung

AU - Han, Seung Gyu

AU - Han, In Mee

AU - Kwon, Young Eun

AU - Park, Kyoung Sook

AU - Lee, Mi Jung

AU - Park, Jung Tak

AU - Han, Seung Hyeok

AU - Ahn, Sang Hoon

AU - Kang, Shin Wook

AU - Yoo, Tae Hyun

PY - 2017/3

Y1 - 2017/3

N2 - Background: Hepatic steatosis measured with controlled attenuation parameter (CAP) using transient elastography predicts metabolic syndrome in the general population. We investigated whether CAP predicted metabolic syndrome in chronic kidney disease patients. Methods: CAP was measured with transient elastography in 465 predialysis chronic kidney disease patients (mean age, 57.5 years). Results: The median CAP value was 239 (202-274) dB/m. In 195 (41.9%) patients with metabolic syndrome, diabetes mellitus was more prevalent (105 [53.8%] vs. 71 [26.3%], P < 0.001), with significantly increased urine albumin-to-creatinine ratio (184 [38-706] vs. 56 [16-408] mg/g Cr, P = 0.003), high sensitivity C-reactive protein levels (5.4 [1.4-28.2] vs. 1.7 [0.6-9.9] mg/L, P < 0.001), and CAP (248 [210-302] vs. 226 [196-259] dB/m, P < 0.001). In multiple linear regression analysis, CAP was independently related to body mass index (β = 0.742, P < 0.001), triglyceride levels (β = 2.034, P < 0.001), estimated glomerular filtration rate (β = 0.316, P = 0.001), serum albumin (β = 1.386, P < 0.001), alanine aminotransferase (β = 0.064, P = 0.029), and total bilirubin (β = -0.881, P = 0.009). In multiple logistic regression analysis, increased CAP was independently associated with increased metabolic syndrome risk (per 10 dB/m increase; odds ratio, 1.093; 95% confidence interval, 1.009-1.183; P = 0.029) even after adjusting for multiple confounding factors. Conclusion: Increased CAP measured with transient elastography significantly correlated with and could predict increased metabolic syndrome risk in chronic kidney disease patients.

AB - Background: Hepatic steatosis measured with controlled attenuation parameter (CAP) using transient elastography predicts metabolic syndrome in the general population. We investigated whether CAP predicted metabolic syndrome in chronic kidney disease patients. Methods: CAP was measured with transient elastography in 465 predialysis chronic kidney disease patients (mean age, 57.5 years). Results: The median CAP value was 239 (202-274) dB/m. In 195 (41.9%) patients with metabolic syndrome, diabetes mellitus was more prevalent (105 [53.8%] vs. 71 [26.3%], P < 0.001), with significantly increased urine albumin-to-creatinine ratio (184 [38-706] vs. 56 [16-408] mg/g Cr, P = 0.003), high sensitivity C-reactive protein levels (5.4 [1.4-28.2] vs. 1.7 [0.6-9.9] mg/L, P < 0.001), and CAP (248 [210-302] vs. 226 [196-259] dB/m, P < 0.001). In multiple linear regression analysis, CAP was independently related to body mass index (β = 0.742, P < 0.001), triglyceride levels (β = 2.034, P < 0.001), estimated glomerular filtration rate (β = 0.316, P = 0.001), serum albumin (β = 1.386, P < 0.001), alanine aminotransferase (β = 0.064, P = 0.029), and total bilirubin (β = -0.881, P = 0.009). In multiple logistic regression analysis, increased CAP was independently associated with increased metabolic syndrome risk (per 10 dB/m increase; odds ratio, 1.093; 95% confidence interval, 1.009-1.183; P = 0.029) even after adjusting for multiple confounding factors. Conclusion: Increased CAP measured with transient elastography significantly correlated with and could predict increased metabolic syndrome risk in chronic kidney disease patients.

UR - http://www.scopus.com/inward/record.url?scp=85034852774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034852774&partnerID=8YFLogxK

U2 - 10.23876/j.krcp.2017.36.1.48

DO - 10.23876/j.krcp.2017.36.1.48

M3 - Article

AN - SCOPUS:85034852774

VL - 36

SP - 48

EP - 57

JO - Kidney Research and Clinical Practice

JF - Kidney Research and Clinical Practice

SN - 2211-9132

IS - 1

ER -